
The company said the late-stage study in generalized myasthenia gravis was likely to miss its efficacy targets, with no safety concerns identified.
Novartis has stopped a late-stage study of remibrutinib in generalized myasthenia gravis after an analysis indicated the treatment was likely to miss its efficacy targets. The company said it had found no safety concerns.
Novartis announced the decision alongside its third-quarter results on Tuesday. It said the move would not affect ongoing studies of remibrutinib for other conditions.
Chief Executive Vas Narasimhan said the drug was unlikely to be significantly better than the current standard treatment in the discontinued study. He said remibrutinib could still become the company’s highest-selling medicine.
As of 15:17 UTC Tuesday, Novartis shares traded at CHF 128.74, up 0.99% since the previous close.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.